GEMoaB_Signet_RGB-500px.png

Next Generation Immunotherapies

GEMoaB_1600x900px_Startseite_V4-01.jpg
 
 

GEMoaB aspires to become a leading, fully integrated biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of next generation immunotherapies for patients in underserved cancer indications.

 
 
#107c5f.png
 

We are hiring!

 
#94c11c.png
 

GEMoaB develops next generation immunotherapies against hard-to-treat blood and solid tumor cancers

 
GEOmaB_1600x900px_Shareholder-01.jpg
 

GEMoaB GmbH is a privately-owned, clinical-stage biopharmaceutical company based in Dresden, Germany. GEMoaB has a broad pipeline of next generation immunotherapy product candidates in pre-clinical and clinical development for the treatment of hematological malignancies as well as solid tumors.

We are a passionate and young team of innovative scientists and clinical experts who thrive to push forward the boundaries of modern cancer therapy.

 
GEMoaB_Icon_Platforms.png

Fully addressing the limitations of current T-Cell-based therapies through our proprietary next generation ATAC, UniCAR and RevCAR platforms.

GEMoaB_Website_Icons-03_Zeichenfläche 1 Kopie.png

Broad pre-clinical and clinical stage pipeline with four assets planned to be in clinical development in solid tumors and hematological malignancies by the end of 2019; highly productive research engine with two additional investigational new drugs for our UniCAR/RevCAR platform expected within the next 18 months.

GEMoaB_Icon_Cooperation.png

Proven expertise in manufacturing cellular immunotherapies through our sister company CELLEX, a world leader in blood stem cell products mastering all aspects of cell therapy including harvest, manipulation, expansion, scheduling and logistics.

#107c5f.png